Botulinum toxin A topical - Allergan

Drug Profile

Botulinum toxin A topical - Allergan

Alternative Names: ANT 1207; Botulinum toxin type A topical lotion

Latest Information Update: 06 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anterios
  • Developer Allergan
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris; Facial-wrinkles; Hyperhidrosis

Most Recent Events

  • 01 Feb 2016 Anterios completes a phase II trial in Hyperhidrosis in USA (NCT02479139)
  • 07 Jan 2016 Anterios has been acquired by Allergan
  • 28 Aug 2015 Phase-II development is ongoing for acne vulgaris, facial wrinkles and hyperhidrosis in USA (Topical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top